van Stekelenborg, John http://orcid.org/0000-0002-5352-3281
Ellenius, Johan
Maskell, Simon
Bergvall, Tomas
Caster, Ola
Dasgupta, Nabarun
Dietrich, Juergen
Gama, Sara
Lewis, David
Newbould, Victoria
Brosch, Sabine
Pierce, Carrie E.
Powell, Gregory
Ptaszyńska-Neophytou, Alicia
Wiśniewski, Antoni F. Z.
Tregunno, Phil
Norén, G. Niklas
Pirmohamed, Munir
Funding for this research was provided by:
Innovative Medicines Initiative (115632)
Article History
First Online: 24 August 2019
Compliance with Ethical Standards
:
: The WEB-RADR project has received support from the Innovative Medicine Initiative Joint Undertaking (ExternalRef removed) under Grant Agreement no 115632, resources of which are composed of financial contributions from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in-kind contribution.
: The following authors have declared no potential conflicts of interest: John van Stekelenborg, Johan Ellenius, Simon Maskell, Tomas Bergvall, Ola Caster, Nabarun Dasgupta, Juergen Dietrich, Victoria Newbould, Sabine Brosch, Carrie E. Pierce, Alicia Ptaszyńska-Neophytou, Phil Tregunno, G. Niklas Norén. Sara Gama is an employee of Novartis. David Lewis is an employee of Novartis and a shareholder of Novartis and GlaxoSmithKline. Gregory Powell is an employee and shareholder of GlaxoSmithKline. Antoni Wisniewski is an employee of AstraZeneca and shareholder of AstraZeneca and GlaxoSmithKline; Munir Pirmohamed received funding from the EU IMI funding scheme for Web-RADR as described in the manuscript.